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Background: Lavender remedies have been used in traditional medicine because of antimicrobial, anti-inflammatory
and mood alleviating effects, but underlying molecular mechanisms are not yet fully elucidated. Recently, studies
investigating the effects of lavender oil in the context of psychiatric disorders have indicated potent pharmacological
properties. Metabolism of tryptophan by indoleamine 2,3-dioxygenase (IDO) was found to provide a biochemical link
between immunology and neuroendocrinology and to be a frequent target of natural products.
Methods: In this in vitro study, interferences of lavender oil and constituents (−)-linalool, (+)-α-pinene and (+)-limonene
with tryptophan catabolism by IDO and formation of neopterin via guanosine triphosphate (GTP)-cyclohydrolase-I and
of interferon-γ have been investigated using unstimulated and phytohemagglutinin (PHA)-stimulated human peripheral
blood mononuclear cells (PBMC).
Results: Treatment with lavender oil dose-dependently suppressed PHA-induced tryptophan breakdown and
kynurenine formation. Similar effects were observed for the three constituents. In parallel, formation of neopterin and
interferon-γ was diminished upon lavender oil treatment. In unstimulated PBMC, effect of lavender oil treatment was
similar, but less pronounced.
Conclusion: Data from this in vitro study suggest that lavender oil treatment might contribute to the modulation
of the immune and neuroendocrine system by interfering with activation-induced tryptophan breakdown and
IDO activity.
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Lavender (Lavandula angustifolia) essential oil consists
of a mixture of mono- and sesquiterpenoid alcohols,
esters, oxides and ketones, containing linalool, linalyl
acetate, 1,8-cineole, terpinen-4-ol, β-caryophyllene and
camphor as primary components [1,2].
Lavender and its essential oil have been used since
centuries due to antiseptic, antimicrobial and sedative
effects. In today’s folk and complementary medicine, the
oil is applied also for the treatment of conditions such as
anxiety, restlessness, insomnia and depression. Adminis-
tration routes include absorption via the respiratory tract
(aromatherapy) or oral ingestion [3]. Although there is* Correspondence: dietmar.fuchs@i-med.ac.at
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unless otherwise stated.evidence-based information on the pharmaceutical effi-
cacy of lavender oil for the treatment of anxiety-related
disturbances [4], its therapeutic significance was little
appreciated for a long time, due to the lack of larger
clinical trials, but also due to methodological problems
in constituent identification and standardization of such
complex multicomponent preparations.
Recently, Kasper et al. demonstrated the therapeutic
efficacy of the lavender oil preparation Silexan for the treat-
ment of subsyndromal anxiety disorder in a randomized,
double-blind, placebo controlled trial [5]. Lavender oil
treatment was found to alleviate anxiety related symptoms
such as restlessness, disturbed sleep as well as somatic
complaints, whereby the product demonstrated good
tolerability without provoking greater adverse effects [6].
However, only few reports on the specific neurobiochem-
ical actions of lavender oil are available. Best discussedl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inflammatory effects of one of the oil’s principal com-
ponents, linalool and its derivatives like linalyl acetate
[7]. The antinociceptive potential of linalool was studied
in several animal studies, e.g. it has been shown to inter-
fere with glutamatergic transmission in mice [8,9] and to
modify the nicotinic receptor-ion channel kinetics at the
neuromuscular junction [10].
Importantly, immune activation and inflammation are
strongly associated with an increase of mood disorders
[11,12]. Several biochemical links between psychoneuro-
immunology and neuropsychopharmacology have been
dissected in the past. The catabolism of the essential
amino acid tryptophan, known for its essential role in
antimicrobial defence, has turned out as an important
link between the immunological network and neuroen-
docrine functions [12,13]. The enzyme indoleamine 2,3-
dioxygenase (IDO, EC 1.13.11.52) catalyses the rate-limiting
step in the conversion of tryptophan to kynurenine and be-
comes highly activated in macrophages and is induced also
in many other cell types upon exposure to pro-inflamma-
tory cytokine interferon-γ (IFN-γ) signaling in the course of
the cellular immune response [12]. Tryptophan depletion
creates an anti-proliferative environment against target cells
and contributes to the antimicrobial effects of activated
macrophages [14]. However, a reduction in plasma trypto-
phan leads in consequence to low serotonin (5-HT)
synthesis and further, several tryptophan breakdown
products are known to exert neuroactive effects [11].
During the cellular immune response, in parallel to IDO,
guanosine triphosphate (GTP)-cyclohydrolase-I (GTP-
CH-I, EC 3.5.4.16) is induced by IFN-γ. GTP-CH-I is the
key enzyme in the biosynthesis of neopterin, a marker
molecule for immune system activation [15,16]. As tryp-
tophan metabolism may occur not only via IDO but also
via hepatic tryptophan 2,3-dioxygenase (TDO), a con-
comitant determination of immune activation marker
neopterin is suitable to judge the contribution of inflam-
mation in changes of tryptophan levels [12]. Neopterin
levels and kynurenine to tryptophan ratio (Kyn/Trp) have
turned out as useful markers for a variety of diseases that
are associated with chronic immune activation such as
infections, autoimmune syndromes, malignancies or
neurodegeneration [12,16].
The aim of this study was to evaluate the effects of lav-
ender essential oil and some of its constituents on tryp-
tophan catabolism, by using the well established model
system of freshly isolated human peripheral blood mono-
nuclear cells (PBMC), stimulated or not with the mitogen
phytohemagglutinin (PHA) [17]. Determination of Kyn/
Trp and neopterin levels in cell culture supernatants is
used as sensitive and reliable read-out for the activation
status of PBMCs. The terpene alcohol (−)-linalool, a
major constituent of lavender oil that is also contained inseveral edible plant species, as well as two minor lavender
oil constituents (+)-α-pinene and (+)-limonene were
chosen as reference compounds for analysis, due to their
reported anti-inflammatory properties [18,19].
Methods
Chemicals
Phytohemagglutinin (PHA), (+)-α-pinene, (−)-linalool
and (+)-limonene were purchased from Sigma Aldrich
(Vienna, Austria). Freshly prepared lavender oil (Aether-
oleum Lavanduli) was purchased from a local pharmacy
(Tiroler Adler Apotheke, Innsbruck, Austria).
Analytical methods
Analyses of lavender oil were performed on a Perkin-
Elmer Autosystem gas chromatograph (Norwalk, USA)
equipped with FID, split-splitless injector and a Perma-
bond SE-54-DF capillary column (50 m x 0.32 ID;
0.25 μm film thickness) from Macherey-Nagel (Düren,
Germany). Helium (1 mL/min) was used as carrier gas,
and injector and detector temperatures were set to 220
and 240°C, respectively. The injected sample volume was
0.5 μL with a split ratio of 1:4. The following temperature
gradient was applied for all separations: for the first
10 min isotherm at 85°C, then the temperature was
increased to 180°C (10°C/min), to keep this setting for
5.5 min. For GC analysis, 60.0 mg of essential oil
was dissolved in 5.00 mL dichloromethane (Chromasolv;
Riedel-de-Haen, Seelze, Germany). For preparation of the
standard solutions 30.0 mg of each compound ((+)-α-
pinene, (−)-linalool and (+)-limonene) was placed in one
5.00 mL volumetric flask, which was filled up to volume
with DCM (level 1). Further concentration levels were
prepared by serial dilution using the same solvent, so that
the covered linear range was from 6.0 to 0.08 mg/mL for
all compounds. External calibration curves were con-
structed for the three available reference compounds,
and the following regression equations were obtained:
y = 14429 x – 336.59 ((+)-α-pinene), y = 16024 x – 902.95
((+)-limonene) and y = 15780 x – 1407.70 ((−)-linalool).
The respective correlation coefficients were 0.9997 or
higher.
Isolation of human PBMC
The study was performed in accordance with the Helsinki
declaration. PBMC were isolated from whole blood ob-
tained from healthy donors of whom informed consent
was obtained that their donated blood might be used for
scientific purposes in case when it was not selected for
transfusion. The local ethics committee confirmed that no
further approval is required for using anonymized leftover
specimens from blood donations of the local blood bank
for scientific purposes. Separation of blood cells was per-
formed by density centrifugation (Lymphoprep, Nycomed
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isolation, PBMC were washed three times in phosphate
buffered saline containing 1 mM EDTA. Cells were
cultivated in RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum (Biochrom, Berlin, Germany),
2 mM L-glutamine (Serva, Heidelberg, Germany) and
50 μg/mL gentamicin (Bio-Whittaker, Walkersville, MD) at
37°C in a humidified atmosphere containing 5% CO2.
Cell treatment
In brief, isolated PBMC were seeded at a density of
1.5 × 106 cells/mL in supplemented RPMI 1640 medium
and pre-incubated for 30 min with or without differ-
ent concentrations of lavender oil [0.1 – 5%] or con-
stituents ((+)-α-pinene [31.25 – 250 μM], (−)-linalool
[25 – 1000 μM] and (+)-limonene [50 – 250 μM]). Then,
cells were stimulated or not with 10 μg/mL PHA for
48 h. For each of the experiments run in duplicates,
PBMC were prepared freshly from blood of at least three
different healthy donors [20].
Cell viability
CellTiter-Blue assay (Promega, Germany) was used to
determine cell viability. The half maximal (50% inhibitory)
concentration (IC50) was calculated by using the CalcuSyn
software (Biosoft, UK) [21].
Measurement of tryptophan, kynurenine, neopterin and
IFN-γ concentrations
After 48 h of incubation, the accumulated tryptophan
breakdown and neopterin formation reach a plateau
[17,20]. PBMC supernatants were harvested by cen-
trifugation. Tryptophan and kynurenine concentrations
were measured by high performance liquid chromatog-
raphy (HPLC) using 3-nitro-L-tyrosine as an internal
standard [22]. To estimate the activity of IDO, Kyn/Trp
was calculated and expressed as μmol kynurenine/mmol
tryptophan. Neopterin and IFN-γ concentrations were
measured by ELISA (BRAHMS, Hennigsdorf/Berlin,
Germany and R&D, Biomedica, Vienna, Austria) accord-
ing to the manufacturers’ instructions with a detection
limit of 2 nmol/L neopterin and 8 pg/mL IFN-γ. Due to
limited sample volumes, IFN-γ measurements were per-
formed in a smaller set of 32 lavender oil treated samples
only.
Statistical analysis
Data were analysed by using the Statistical Package
for the Social Sciences (version 19, SPSS, Chicago,
III, USA). To take into account that not all collected
data followed a normal distribution, non-parametric
Friedman and Wilcoxon signed-rank test were applied.
P-values below 0.05 were considered to indicate signifi-
cant differences.Results
GC analysis
The three compounds (+)-α-pinene, (−)-linalool and
(+)-limonene could be separated with GC and assigned in
lavender essential oil (Figure 1). The respective retention
times were found to be 5.72 min ((+)-α-pinene), 8.34 min
((+)-limonene) and 11.38 min ((−)-linalool). Their content
in the essential oil sample was 3.70% (σrel = 0.29; n = 3) for
(+)-α-pinene, 1.29% (σrel = 0.11) for (+)-limonene, and
33.09% (σrel = 0.64) for (−)-linalool.
Effect of lavender oil and its constituents on
cell viability
Cytotoxicity was evaluated after 48 h incubation with
lavender oil in a concentration range from 0.2 to 5.0% in
unstimulated and PHA-stimulated PBMC. Treatment
with the mitogen PHA [10 μg/mL] resulted in a signifi-
cant increase of cell number due to the stimulated cell
growth (Figure 2A). Reduced viability in the presence of
lavender oil was measured with 0.5% addition in unstimu-
lated and with 1.0% in PHA-stimulated cells, indicating
the beginning of cytotoxic effects for higher treatment
concentrations (Figure 2B). Viability decreased in a dose
dependent manner, with IC50 values of 2.29% in unstimu-
lated and 1.79% in stimulated cells.
No cytotoxic effects in the tested concentration ranges
could be observed for (−)-linalool (IC50 ≥ 1000 μM) and
(+)-limonene (IC50 ≥ 250 μM), while for (+)-α-pinene
IC50 values of 195.41 μM in unstimulated PBMC and
127.36 μM in PHA-stimulated PBMC were determined.
Effect of lavender oil and its constituents on tryptophan
breakdown
After an incubation period of 48 h, the average trypto-
phan concentration in supernatants of unstimulated
PBMC was 31.5 ± 1.7 μmol/L (mean ± SEM; 85.2 ± 4.7%
of initial medium content) and the mean kynurenine
concentration was 2.3 ± 0.7 μmol/L, resulting in Kyn/
Trp of 79.0 ± 28.0 μmol/mmol (Figure 3). Upon
stimulation of cells with PHA, tryptophan levels de-
creased to 11.3 ± 3.8 μmol/L, while the mean kynure-
nine concentration increased to 13.1 ± 3.3 μmol/L.
The Kyn/Trp was increased in PHA-treated samples
approximately 100-fold in comparison to the unstimu-
lated supernatants (all P < 0.05).
By addition of lavender oil [0.1 – 5.0%] to unstimu-
lated PBMC, no change of tryptophan concentrations
but a significant decline of kynurenine and Kyn/Trp
levels was apparent with the treatment concentrations of
0.2 to 5.0% (Figure 4). In PHA-stimulated PBMC, laven-
der oil suppressed tryptophan breakdown significantly
at all treatment concentrations (0.1 to 5.0%), Kyn/Trp
and kynurenine levels dropped dose-dependently and
significantly (Figure 4). Addition of 1.0% of lavender oil
Figure 1 Determination of (+)-α-pinene, (−)-linalool and (+)-limonene in lavender oil. GC analysis of a standard mixture (A) and lavender
essential oil (B).
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tryptophan levels comparable to the concentration in
unstimulated cell supernatants (79.4 ± 3.0% of medium
content).
While in PHA-treated cells, the incubation with 0.5%
of lavender oil resulted in a suppression of kynurenine
to 19.9 ± 5.7% of PHA control, the same concentration
decreased kynurenine levels only to 50.2 ± 10.1% in
unstimulated supernatants (compared to unstimulated
control). The effect of lavender oil on IDO activity as
indicated by Kyn/Trp was also significantly reduced in
both, mitogen-stimulated and unstimulated PBMC. Like-
wise, this effect was more striking in PHA-stimulated
cells, where 0.5% of lavender oil addition resulted in a
reduction of IDO activity to 8.5 ± 2.2% compared to the
PHA control. The same lavender concentration decreased
Kyn/Trp only to 51.4 ± 11.3% in unstimulated PBMC
(compared to unstimulated controls). Overall, lavender oilinduced effects were more pronounced in PHA-stimulated
cells than in unstimulated ones.
Neither (−)-linalool treatment (up to 1000 μM) nor
(+)-limonene addition (up to 250 μM) resulted in a
significant change of the Kyn/Trp ratio in unstimu-
lated PBMC (Figure 5A). (+)-α-pinene did not affect
IDO activity up to a concentration of 125 μM. Treat-
ment of unstimulated PBMC with (+)-α-pinene at
already cytotoxic concentrations (250 μM) resulted in a
Kyn/Trp decrease of 19.4 ± 8.0% (Figure 5A). In PHA-
stimulated cells, all constituents were able to strongly
and significantly inhibit IDO activity in a dose-dependent
manner at non-toxic concentrations (Figure 5B). With
(+)-limonene and (+)-α-pinene, lower treatment con-
centrations led to a decrease of the Kyn/Trp ratio in
stimulated cells (25 μM and 62.5 μM, respectively)
than with (−)-linalool, were the inhibitory effect started
with 125 μM.
Figure 2 Effect of lavender oil on cell viability. (A) Viability of PBMC cells after treatment with (black bars) or without PHA (white bars) (*P < 0.05,
compared to unstimulated control). (B) Viability of unstimulated (white bars) and PHA-stimulated (black bars) PBMC after incubation with increasing
concentrations of lavender oil for 48 h, expressed as % of baseline (*P < 0.05, compared to cells without added lavender oil). Results shown are the
mean values ± SEM of two independent experiments run in triplicates.
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After 48 h, neopterin concentrations were significantly
higher (10.5 ± 1.8 nmol/L) in culture supernatant of
PHA-stimulated cells than in supernatants of unstimu-
lated PBMC (3.8 ± 0.3 nmol/L) (p < 0.05; Figure 6A).
Also, IFN-γ levels were increased in mitogen stimulated
cells (209.7 ± 73.4 pg/mL) in comparison to untreated
cells (19.3 ± 14.5 pg/mL) (P < 0.05).
The incubation of unstimulated PBMC with lavender
oil resulted in the reduction of neopterin levels at allFigure 3 Effect of PHA stimulation in PBMCs. Indoleamine 2,3-dioxygen
in μmol/mmol, note log scale) (A) and concentrations of kynurenine (B) an
(black bars) PBMC. Results shown are the mean values ± SEM of four indep
unstimulated cells).treatment concentrations (Figure 6B). At a concentration
of 0.5% lavender oil and higher, neopterin formation was
maximally decreased to 85.4 ± 3.4% in comparison to the
untreated control cells. In PHA-stimulated cells, neopterin
concentrations were significantly and dose-dependently
lowered in the concentration range from 0.5 - 5.0% of lav-
ender oil, with a reduction to 67.6 ± 15.5% at 0.5% lavender
oil treatment, in comparison to the PHA-treated control.
IFN-γ concentrations were not affected in unstimulated
PBMC upon lavender oil treatment, while in stimulatedase activity, expressed as the kynurenine to tryptophan ratio (Kyn/Trp
d tryptophan (C) in unstimulated (white bars) and PHA-stimulated
endent experiments run in duplicates (*P < 0.05, compared to
Figure 4 Effect of lavender oil on tryptophan metabolism. Effect of lavender oil on the kynurenine to tryptophan ratio (Kyn/Trp; A), kynurenine (B)
and tryptophan (C) concentrations in unstimulated (white circles) and PHA-stimulated PBMC (black triangles), expressed as % of baseline (control cells
treated with or without PHA). Tryptophan concentrations are expressed as % of medium control. Results shown are the mean values ± SEM of four
independent experiments run in duplicates (*P < 0.05, compared to baseline).
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(data not shown). Addition of 0.5% of lavender oil resulted
in a reduction of IFN-γ production until baseline levels of
unstimulated cells (22.4 ± 5.9 pg/mL).
Discussion
Anti-inflammatory properties of lavender oil and its con-
stituents have been reported in several in vitro and
in vivo studies. Lavender essential oil and constituents
have been shown to interfere with key immunological
pathways, e.g. nuclear factor kappa B (NF-κB) and p38
mitogen-activated protein kinase (MAPK) signaling asFigure 5 Effect of (+)-α-pinene, (−)-linalool and (+)-limonene on trypt
kynurenine to tryptophan ratio (Kyn/Trp) in (A) unstimulated (white symbo
baseline (control cells treated with or without PHA). Results shown are
duplicates (*P < 0.05, compared to baseline).well as cytokine secretion [19,23]. E.g., (+)-α-pinene,
(−)-linalool and (+)-limonene were able to decrease
interleukin-2 (IL-2) secretion and to increase the IL-10/
IL-2 ratio in mouse primary splenocytes, which indi-
cates their property to repress Th1 immune activation
and suggest a potential inclination towards Th2 [19].
Furthermore, (−)-linalool was able to attenuate the
production of lipopolysaccharide (LPS)-induced tumor
necrosis factor α (TNFα) and IL-6 both in RAW 264.7
macrophages and in mice, and has been discussed as
potential anti-inflammatory agent for preventing lung
injury [19,23].ophan metabolism. Effect of the lavender oil constituents on the
ls) and (B) PHA-stimulated PBMC (black symbols), expressed as % of
the mean values ± SEM of three independent experiments run in
Figure 6 Effect of lavender oil on neopterin production. (A) Concentration of neopterin in unstimulated (white bar) and PHA-stimulated
PBMC (black bar) (*P < 0.05, compared to unstimulated control). (B) Neopterin concentrations expressed as % of baseline (control cells treated
with or without PHA) in the supernatants of unstimulated (white circles) and PHA-stimulated PBMC (black triangles), incubated with increasing
concentrations of lavender oil for 48 h. Results shown are the mean values ± SEM of four independent experiments run in duplicates (*P < 0.05,
compared to baseline).
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Th1 immune response agrees with results of our study,
which showed that non-toxic concentrations of (+)-α-
pinene, (−)-linalool and (+)-limonene were able to inhibit
mitogen-stimulated IDO activity in a model system of
freshly isolated PBMC.
Also, lavender oil treatment was able to dose-
dependently inhibit both tryptophan breakdown and
kynurenine formation in supernatants of mitogen-
stimulated PBMC. This inhibitory effect could already be
detected at lavender oil concentrations that affected cell
viability only slightly (0.1 to 0.5%). At higher treatment
concentrations, effects on tryptophan and kynurenine
were even stronger, however also cytotoxic effects of lav-
ender oil increased. Interestingly, it has been shown that
kynurenine metabolites are able to induce Th1 cell apop-
tosis [24]. Thus, we suggest that at low concentrations,
lavender oil might beneficially influence cell viability by
counteracting pro-apoptotic signaling, while at higher
concentrations toxicity effects become prevalent. In stud-
ies with several compounds in the PBMC model [17,20],
IDO inhibition preceded substance toxicity phenomena,
thus probably being a more sensitive indicator of cell
death. Of note, the viability assay used in this study is
based on the reduction of resazurin to fluorescent
resorufin. Increased conversion rates may also indicate
enhanced metabolic activity of cells, which does not
always correlate with an increase in proliferation [25,26].
Importantly, in mitogen-stimulated cells, a suppressive
effect of lavender oil treatment on neopterin and IFN-γconcentrations could be observed. In unstimulated cells,
lavender oil treatment had no influence on tryptophan
and IFN-γ levels, but the formation of kynurenine and
neopterin was suppressed to some extent. As PBMC
were preincubated with the lavender oil before PHA
addition, we suggest that the oil interferes mainly with
IDO and GTP-CH-I stimulation. A basal activity of both
enzymes is suggested to be present also in unstimu-
lated cells, probably initiated due to the preceding
cell isolation procedure. In unstimulated PBMC, tryp-
tophan levels remained unaffected upon lavender oil
treatment, e.g. with a 0.5% oil addition, 86.8 ± 3.2% of
the initial medium content of tryptophan, correspond-
ing to ~ 32 μmol/L, was still detectable after 48 h, while a
significant reduction of kynurenine levels was observed.
For 0.5% lavender oil treatment, kynurenine levels were re-
duced to 50.2 ± 10.1% compared to the untreated control,
which corresponds to a reduction from 2.3 ± 0.7 μmol/L to
0.8 ± 0.1 μmol/L.
Of note, changes in immune parameters, such as im-
paired activities of immunocompetent cells, and involve-
ment of inflammatory mediators and pro-inflammatory
cytokines have been reported to be associated with behav-
ioural alterations by several studies, and cell-mediated im-
mune activation is suggested to be an important factor in
distinct mental disturbances [11]. Behavioural changes can
be induced by altered cytokine levels, e.g. studies of IFN-α
treated patients showed therapy-induced depressive symp-
toms associated with activation of neuroendocrine path-
ways and altered serotonin metabolism [11,27]. Within
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are strongly induced, including neopterin production via
GTP-CH-I and tryptophan catabolism via IDO, and the
concentrations of these biomarkers have been found to be
altered in mental disorders or diseases associated mood
disturbances [12]. Enhanced neopterin concentrations
together with low serum levels of tryptophan caused by
increased tryptophan breakdown were shown to correlate
with neuropsychiatric abnormalities like cognitive decline
and depressive symptoms especially in long-lasting and
chronic diseases [28].
Beside the important role of tryptophan catabolism in
the regulation of inflammatory responses [29], tryptophan
is a source for the production of 5-hydroxytryptophan, an
intermediate in the biosynthesis of neurotransmitter sero-
tonin. In states of persistent immune activation, availability
of free serum tryptophan is diminished and as a conse-
quence of reduced serotonin production, serotonergic
functions may as well be affected [12].
About 95% of the body’s serotonin resides in the gut
[30]. Furthermore, the gastrointestinal tract is rich in
lymphocytes. Lavender oil treatment concentrations used
for this in vitro study may appear relatively high, however
in vivo, initial effects on IDO are suggested to be initiated
already in the gastrointestinal tract, were such concentra-
tions can be readily reached. In the study of Kasper et al.,
a treatment concentration of 80 mg/day was able to
induce clinically meaningful and statistically significant
anxiolytic effects [5].
Of note, deciphering specific bioactivities of isolated
essential oil components is challenging because of the
great number of constituents with similar physicochemi-
cal properties (e.g. lipophilic, high vapor pressure). In
general, the major components reflect quite well the
features of the essential oils from which they derive [31].
However minor constituent may contribute to the over-
all activity profile by modulating these activities and
synergisms can play a major role [32]. (−)-Linalool is the
most studied monoterpene regarding analgesic effects, a
more detailed elucidation of its impact on the GABAergic
system would help to dissect molecular details on its anti-
convulsant, analgesic as well as anxiolytic activities [33].
For both (+)-limonene [34] and (+)-α-pinene [35] antinoci-
ceptive effects have been reported, however these effects
are suggested to be strongly associated with their anti-
inflammatory activities [33].
The here reported effect on tryptophan breakdown is
not a unique property of lavender oil or the analysed
constituents. In earlier studies using the identical cell-
biological assay, similar effects on tryptophan metabolism
have been found by investigating Hypericum perforatum
extracts as well as Δ9-tetrahydrocannabinol and cannabi-
diol, indicating that the suppression of tryptophan break-
down and neopterin production might be an importantbut a more general aspect in the action of psychoactive
compounds [36,37]. Thus, although our findings are from
in vitro experiments only, they might be relevant also for
the in vivo situation.
Furthermore, kynurenine derivatives such as kynurenic
and quinolinic acid and 3-hydroxykynurenine are known
to be neuroactive and their hyper- or hypofunction is
associated with neurological disorders and psychiatric
diseases such as depression and schizophrenia [38]. The
quinolinic acid to kynurenic acid ratio in the brain is
discussed as a potential measure for conditions linked to
excitotoxicity. Although both substances must be synthe-
sized locally, because they are not able to cross the blood–
brain barrier, other kynurenine pathway components
such as tryptophan, kynurenine and 3-hydroxykynurenine
can enter the brain, thus establishing a link between
peripheral inflammation and brain tryptophan metabolism
[39]. Additionally, also microglial cells and blood-borne
cells within the brain can be stimulated to activate the
kynurenine pathway in states of peripheral immune
activation [38].
Scientific reports on the impact of IDO activity for
different pathological conditions, including neuropsychi-
atric disturbances, account for IDO as a potential key
pharmacological target. Several IDO inhibitors have been
identified yet, and much effort will be necessary to evalu-
ate their in vivo efficacy. The most prominent IDO
inhibitor1-methyl tryptophan (1-MT) has been shown to
counteract microbial-induced depressive-like symptoms in
animal studies [40]. Beside the synthetic design of IDO
antagonists via rational design strategies, also a variety of
endogenous and exogenous antioxidants, such as vitamins,
food supplements or preservatives, have been shown to
suppress tryptophan catabolism in cellular model systems
[17,20]. Thereby, the modulation of tryptophan metabol-
ism is suggested to be due to the interference of the test
substances mostly with immune activation cascades,
rather than directly with IDO enzyme, as often other
immune-relevant molecules such as neopterin and IFN-γ
are affected additionally. Also in this study, lavender oil
treatment was able to reduce neopterin and IFN-γ levels
in mitogen-treated PBMC.
Moreover, the increased production of neopterin dur-
ing inflammation could also indirectly affect neurotrans-
mitter concentrations. In human macrophages, neopterin
is produced at the expense of tetrahydrobiopterin (BH4),
an essential cofactor for several monooxygenases includ-
ing tryptophan, phenylalanine and tyrosine hydroxylase
[15]. Thus, beside serotonin synthesis, also catecholamine
formation depends on BH4 availability. Interestingly, in
depressed patients with a history of seasonal affective dis-
order, significantly lower plasma biopterin and tryptophan
levels but elevated neopterin levels were found in com-
parison to healthy controls [41]. Thus, reduced BH4 levels
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Conclusion
We could show that lavender oil can suppress mitogen-
induced tryptophan degradation and IFN-γ production
in vitro, and influence on kynurenine and neopterin
formation in activated as well as to a lower extent in
unstimulated PBMC.
Also, the constituents (−)-linalool, (+)-α-pinene and
(+)-limonene showed dose-dependent inhibitory effects
on tryptophan breakdown in PHA-stimulated PBMC.
Thus, the IDO suppressing activities of lavender oil might
at least partially result from the concerted action of the
analysed constituents, where also minor components may
play an essential role.
The finding that lavender essential oil, a medicinal plant-
derived natural multicomponent preparation, may be a
source of pharmacological active substances that interfere
with key immune activation cascades such as the IDO and
GTP-CH-I pathway, is of central relevance for the under-
standing of its therapeutic efficacy.
However, as the reported effects might not reflect the
whole activity spectrum of lavender oil. Further research
is necessary to elucidate other neuro-immunological rele-
vant activities and to confirm the in vivo relevance of our
findings.
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